{"id":"finafloxacin","rwe":[{"pmid":"40896792","year":"2025","title":"An evaluation of antibiotic options for the treatment of biothreat pathogens.","finding":"","journal":"Frontiers in antibiotics","studyType":"Clinical Study"},{"pmid":"38289122","year":"2024","title":"Layering vaccination with antibiotic therapy results in protection and clearance of Burkholderia pseudomallei in Balb/c mice.","finding":"","journal":"Infection and immunity","studyType":"Clinical Study"},{"pmid":"37954372","year":"2023","title":"Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China.","finding":"","journal":"Heliyon","studyType":"Clinical Study"},{"pmid":"37508192","year":"2023","title":"In Vitro Activity of Finafloxacin against Panels of Respiratory Pathogens.","finding":"","journal":"Antibiotics (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"37100354","year":"2023","title":"Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials.","finding":"","journal":"International journal of antimicrobial agents","studyType":"Clinical Study"}],"tags":[{"label":"Quinolone Antimicrobial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Acute otitis externa","category":"indication"},{"label":"Fonseca Biosciences","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Anti-Infective Agents, Urinary","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Topoisomerase II Inhibitors","category":"pharmacology"},{"label":"Topoisomerase Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Fonseca Biosciences","patents":[{"applNo":"N206307","source":"FDA Orange Book","status":"Active","expires":"Aug 8, 2031","useCode":"U-1679","territory":"US","drugProduct":false,"patentNumber":"8536167","drugSubstance":false},{"applNo":"N206307","source":"FDA Orange Book","status":"Active","expires":"Nov 21, 2033","useCode":"U-1679","territory":"US","drugProduct":true,"patentNumber":"9504691","drugSubstance":false},{"applNo":"N206307","source":"FDA Orange Book","status":"Active","expires":"Jul 2, 2030","useCode":"U-1679","territory":"US","drugProduct":false,"patentNumber":"9119859","drugSubstance":false},{"applNo":"N206307","source":"FDA Orange Book","status":"Active","expires":"Jul 2, 2030","useCode":"","territory":"US","drugProduct":true,"patentNumber":"9993483","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FINAFLOXACIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:23:13.470431+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:23:13.470319+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:23:19.022728+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FINAFLOXACIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:23:19.373432+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA gyrase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:23:20.444518+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1908370/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:23:20.099548+00:00"}},"allNames":"xtoro","offLabel":[],"synonyms":["finafloxacin","xtoro","finafloxacin hydrochloride","BAY35-3377","finafloxacin HCl"],"timeline":[{"date":"2014-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ALCON RES LTD to Fonseca Biosciences"},{"date":"2014-12-17","type":"positive","source":"DrugCentral","milestone":"FDA approval (Alcon Res Ltd)"}],"aiSummary":"Xtoro (Finafloxacin) is a quinolone antimicrobial small molecule developed by Alcon Res Ltd and currently owned by Fonseca Biosciences. It was FDA-approved in 2014 for the treatment of acute otitis externa. Xtoro works by inhibiting bacterial DNA replication, ultimately leading to bacterial cell death. As of now, it remains a patented product with no generic manufacturers. Key safety considerations include its potential to cause gastrointestinal side effects and photosensitivity.","approvals":[{"date":"2014-12-17","orphan":false,"company":"ALCON RES LTD","regulator":"FDA"}],"brandName":"Xtoro","ecosystem":[{"indication":"Acute otitis externa","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"Quinolone Antimicrobial","explanation":"","oneSentence":"","technicalDetail":"Xtoro exerts its antibacterial effect by targeting the bacterial DNA gyrase and topoisomerase IV enzymes, which are essential for bacterial DNA replication and transcription."},"commercial":{"launchDate":"2014","_launchSource":"DrugCentral (FDA 2014-12-17, ALCON RES LTD)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4920","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FINAFLOXACIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FINAFLOXACIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:31:17.552269","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:23:21.724778+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"finafloxacin","indications":{"approved":[{"name":"Acute otitis externa","source":"DrugCentral","snomedId":30250000,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Fonseca Biosciences","drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01904162","phase":"PHASE1","title":"Effect of Age and Gender on the PK and Tolerability of Finafloxacin","status":"COMPLETED","sponsor":"MerLion Pharmaceuticals GmbH","startDate":"2010-02","conditions":["Pharmacokinetic and Tolerability of Finafloxacin"],"enrollment":40,"completionDate":"2010-02"},{"nctId":"NCT01928433","phase":"PHASE2","title":"Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis","status":"COMPLETED","sponsor":"MerLion Pharmaceuticals GmbH","startDate":"2012-12","conditions":["Urinary Tract Infections","Acute Pyelonephritis"],"enrollment":225,"completionDate":"2015-10"},{"nctId":"NCT01907867","phase":"PHASE1","title":"Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin","status":"COMPLETED","sponsor":"MerLion Pharmaceuticals GmbH","startDate":"2012-01","conditions":["Safety and Tolerability"],"enrollment":18,"completionDate":"2012-02"},{"nctId":"NCT01910883","phase":"PHASE1","title":"Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects","status":"COMPLETED","sponsor":"MerLion Pharmaceuticals GmbH","startDate":"2010-09","conditions":["Healthy"],"enrollment":58,"completionDate":"2012-03"},{"nctId":"NCT00723502","phase":"PHASE2","title":"Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients","status":"COMPLETED","sponsor":"MerLion Pharmaceuticals GmbH","startDate":"2008-09","conditions":["Gram-Negative Bacterial Infections","Helicobacter Infections","Dyspepsia"],"enrollment":30,"completionDate":"2009-04"},{"nctId":"NCT00722735","phase":"PHASE2","title":"Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI)","status":"COMPLETED","sponsor":"MerLion Pharmaceuticals GmbH","startDate":"2008-10","conditions":["Urinary Tract Infections"],"enrollment":36,"completionDate":"2009-04"},{"nctId":"NCT00483158","phase":"PHASE1","title":"First Time in Man Study of Finafloxacin Hydrochloride","status":"COMPLETED","sponsor":"MerLion Pharmaceuticals GmbH","startDate":"2007-08","conditions":["Helicobacter Infections","Urinary Tract Infection"],"enrollment":95,"completionDate":"2008-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"UNII":"D26OSN9Q4R","CHEBI":"CHEBI:85176","INN_ID":"8121","RXNORM":"1598641","UMLSCUI":"C2825286","chemblId":"CHEMBL1908370","ChEMBL_ID":"CHEMBL1908370","KEGG_DRUG":"D10575","DRUGBANK_ID":"DB09047","PUBCHEM_CID":"11567473","SNOMEDCT_US":"708794002","IUPHAR_LIGAND_ID":"10809","SECONDARY_CAS_RN":"209342-41-6","MESH_SUPPLEMENTAL_RECORD_UI":"C560572"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2014-","companyName":"Alcon Res Ltd","relationship":"Original Developer"},{"period":"present","companyName":"Fonseca Biosciences","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"13.42 hours","clearance":"5.75 mL/min/kg","fractionUnbound":"0.75%","volumeOfDistribution":"1.42 L/kg"},"publicationCount":49,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"originalDeveloper":"Alcon Res Ltd","recentPublications":[{"date":"2025","pmid":"40896792","title":"An evaluation of antibiotic options for the treatment of biothreat pathogens.","journal":"Frontiers in antibiotics"},{"date":"2024 Mar 12","pmid":"38289122","title":"Layering vaccination with antibiotic therapy results in protection and clearance of Burkholderia pseudomallei in Balb/c mice.","journal":"Infection and immunity"},{"date":"2023 Nov","pmid":"37954372","title":"Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China.","journal":"Heliyon"},{"date":"2023 Jun 23","pmid":"37508192","title":"In Vitro Activity of Finafloxacin against Panels of Respiratory Pathogens.","journal":"Antibiotics (Basel, Switzerland)"},{"date":"2023 Jul","pmid":"37100354","title":"Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials.","journal":"International journal of antimicrobial agents"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Fonseca Biosciences","companyId":"fonseca-biosciences","modality":"Small molecule","firstApprovalDate":"2014","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-12-17T00:00:00.000Z","mah":"ALCON RES LTD","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-12-17T00:00:00.000Z","mah":"FONSECA BIOSCIENCES","brand_name_local":"XTORO","application_number":"NDA206307"},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:23:21.724778+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}